Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and Bone Sarcoma Group

A. T. van Oosterom, A. Santoro, V. Bramwell, M. Davy, H. T. Mouridsen, D. Thomas, R. Sylvester

Research output: Contribution to journalArticlepeer-review

Abstract

Mitomycin C at a dose of 12 mg/m2 i.v. q 3 weeks was administered to 34 patients with measurable progressive advanced soft tissue sarcomas. No objective response was observed although in one of the 12 patients with overall stabilisation of disease a partial response was reported in lung lesions. The side-effects observed in this group of patients were generally mild. On the basis of this results the application of mitomycin C in this disease cannot be recommended.

Original languageEnglish
Pages (from-to)459-461
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number4
DOIs
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and Bone Sarcoma Group'. Together they form a unique fingerprint.

Cite this